"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 4 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 3 | 3 | 6 |
| 2013 | 1 | 2 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 3 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 2 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. 2025 Feb 01; 48(2):177-181.
-
Emerging Role of Semaglutide and GLP-1 Agonist Medications in Plastic Surgery: A Note of Caution. Plast Reconstr Surg. 2024 09 01; 154(3):629e-631e.
-
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr Opin Nephrol Hypertens. 2024 05 01; 33(3):331-336.
-
Should the Incretin hype be the same for older adults: Promise + cautions. J Am Geriatr Soc. 2024 Jul; 72(7):2266-2268.
-
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
-
Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes. Cell Rep Med. 2022 11 15; 3(11):100813.
-
Diabetes of Unclear Type in an Adolescent Boy With Multiple Islet-cell Autoantibody Positivity Successfully Managed With Glucagon-like Peptide-1 Receptor Agonist Alone: A Case Report. Can J Diabetes. 2023 Feb; 47(1):90-93.
-
Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
-
GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia. J Clin Endocrinol Metab. 2020 08 01; 105(8).
-
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes. Diabetologia. 2020 10; 63(10):2194-2204.